MORPHOMER
LIVE

Serial Number

88636131

Owner

AC Immune SA

Attorney

Kristina Montanaro Schrader

Filing Date

Sep 30, 2019

Add to watchlist:

No watchlists yet
View on USPTO

MORPHOMER Trademark

Serial Number: 88636131

MORPHOMER is a trademark filed by AC Immune SA on September 30, 2019. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

AC Immune SA (8 trademarks)

EPFL Innovation Park, building B

Entity Type: 99

Trademark Details

Filing Date

September 30, 2019

Registration Date

Not Registered

Goods & Services

Pharmaceuticals, medical and veterinary preparations for the diagnosis, prevention and treatment of neurodegenerative diseases and inflammatory diseases; diagnostic preparations and materials for medical or veterinary purposes; companion diagnostic agents, biomarkers, imaging agents, PET-Imaging compounds, all for medical purposes; chemical preparations for medical purposes, namely, for the diagnosis, prevention and treatment of neurodegenerative diseases and inflammatory diseases; chemico-pharmaceutical preparation for medical purposes, namely, for the diagnosis, prevention and treatment of neurodegenerative diseases and inflammatory diseases; pharmaceutical and medical preparations in the nature of small molecule compounds for medical purposes; PET-Imaging compounds in the nature of diagnostic radiopharmaceutical agents for use in PET imaging; diagnostic preparations in the nature of companion compounds for medical use; pharmaceutical and medical preparations in the nature of biomarkers for medical purposes; diagnostic reagents for medical purposes; none of the foregoing in relation to and for antibodies

Scientific and technological services, namely, scientific research, analysis and testing and the development of technology in the field of medicine and pharmaceuticals and research activities relating thereto; providing access to a proprietary technology platform containing small molecules that gives users the ability to obtain information for research purposes; biological research services; chemical research services in the fields of neurodegenerative diseases and inflammatory diseases; medical research services; scientific and medical laboratory services in biotechnology, chemistry, pharmacy, molecular science and immunotherapy; providing medical and scientific research information in the field of biotechnology, chemistry, pharmacy, molecular science, immunotherapy, therapeutics, diagnostics and clinical trials; scientific research, development and consultancy in the field of biotechnology, chemistry, pharmacy, molecular science, immunotherapy, therapeutics, diagnostics and clinical trials; development of test procedures, assays, test reagents, PET-imaging, companion diagnostic biomarkers, and test kits for the field of biotechnology, chemistry, pharmacy, molecular science, immunotherapy, therapeutics, diagnostics and clinical trials; biological research, namely, screening and selection of pharmaceutical active substances from biological and biotechnological preparations; custom design and development of biological assays; none of the foregoing in relation to and for antibodies

Chemicals for use in industry and science; chemical substances, chemical materials and chemical preparations, and natural elements, namely, chemical preparations for industrial and scientific purposes, other than for medical or veterinary use; chemical, biochemical, biological and biotechnological preparations for use in industry and science; chemical preparations comprising small molecules for use in industry and science; molecular libraries, comprising libraries of chemical preparations for use in industry and science; small molecule library, comprising libraries of chemical preparations for use in industry and science; detectably labelled compound for industrial, scientific purposes; diagnostic reagents for industrial, scientific or research purposes; immunological reagents for industrial, scientific or research purposes; diagnostic tools in the nature of preparations, companion diagnostic agents, biomarkers, imaging agents, PET-Imaging compounds for industrial, scientific purposes other than for medical or veterinary use; diagnostic reagents for industrial, scientific or research purposes other than for medical or veterinary use; none of the foregoing in relation to and for antibodies

Filing History

NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Nov 7, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Nov 7, 2025 GNSL
SUSPENSION LETTER WRITTEN
Nov 7, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 7, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 7, 2025 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Nov 5, 2025 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Sep 10, 2025 GNS2
INQUIRY TO SUSPENSION E-MAILED
Sep 10, 2025 GNSI
SUSPENSION INQUIRY WRITTEN
Sep 10, 2025 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jun 4, 2025 RCCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Dec 3, 2024 RCSC
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 2, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 2, 2024 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Dec 2, 2024 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jun 19, 2024 GNS3
LETTER OF SUSPENSION E-MAILED
Jun 19, 2024 GNSL
SUSPENSION LETTER WRITTEN
Jun 19, 2024 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 18, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 18, 2024 CRFA
ASSIGNED TO LIE
Jun 18, 2024 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
May 16, 2024 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Feb 28, 2024 GNS2
INQUIRY TO SUSPENSION E-MAILED
Feb 28, 2024 GNSI
SUSPENSION INQUIRY WRITTEN
Feb 28, 2024 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Dec 6, 2023 RCCK
ASSIGNED TO EXAMINER
Dec 4, 2023 DOCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Nov 30, 2022 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Apr 27, 2022 GNS3
LETTER OF SUSPENSION E-MAILED
Apr 27, 2022 GNSL
SUSPENSION LETTER WRITTEN
Apr 27, 2022 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 14, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 14, 2022 CRFA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 14, 2022 CHAN
ASSIGNED TO LIE
Feb 9, 2022 ALIE
ASSIGNED TO LIE
Jan 31, 2022 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jan 27, 2022 ERSI
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 27, 2022 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 27, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 27, 2022 REAP
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Aug 10, 2021 GNS2
INQUIRY TO SUSPENSION E-MAILED
Aug 10, 2021 GNSI
SUSPENSION INQUIRY WRITTEN
Aug 10, 2021 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jul 6, 2021 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jul 29, 2020 GNS3
LETTER OF SUSPENSION E-MAILED
Jul 29, 2020 GNSL
SUSPENSION LETTER WRITTEN
Jul 29, 2020 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 3, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 3, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 3, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 6, 2020 GNRN
NON-FINAL ACTION E-MAILED
Jan 6, 2020 GNRT
NON-FINAL ACTION WRITTEN
Jan 6, 2020 CNRT
ASSIGNED TO EXAMINER
Jan 3, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 3, 2019 NWOS
NEW APPLICATION ENTERED
Oct 3, 2019 NWAP